Difference between revisions of "Non-small cell lung cancer, MET-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "][" to "] [") |
|||
| Line 4: | Line 4: | ||
|- | |- | ||
| style="background-color:#F0F0F0; width:15%" |[[File:Amit_Kulkarni.jpg|frameless|upright=0.3|center]] | | style="background-color:#F0F0F0; width:15%" |[[File:Amit_Kulkarni.jpg|frameless|upright=0.3|center]] | ||
| − | | style="width:35%" |<big>[[User:Akulkarni|Amit Kulkarni, MBBS]]<br>University of Minnesota<br>Minneapolis, MN</big><br>[[File:Social-twitter-icon.png|frameless|upright=0.1]][https://twitter.com/AmitKulkarniMD AmitKulkarniMD] | + | | style="width:35%" |<big>[[User:Akulkarni|Amit Kulkarni, MBBS]]<br>University of Minnesota<br>Minneapolis, MN</big><br>[[File:Social-twitter-icon.png|frameless|upright=0.1]] [https://twitter.com/AmitKulkarniMD AmitKulkarniMD] |
|style="background-color:#F0F0F0"|[[File:TravisOsterman.jpg|frameless|upright=0.3|center]] | |style="background-color:#F0F0F0"|[[File:TravisOsterman.jpg|frameless|upright=0.3|center]] | ||
| − | |<big>[[User:Travisosterman|Travis Osterman, DO, MS]]<br>Vanderbilt University<br>Nashville, TN</big><br>[[File:Social-twitter-icon.png|frameless|upright=0.1]][https://twitter.com/TravisOsterman TravisOsterman]<br>[https://www.linkedin.com/in/travis-osterman-1850b236/ LinkedIn] | + | |<big>[[User:Travisosterman|Travis Osterman, DO, MS]]<br>Vanderbilt University<br>Nashville, TN</big><br>[[File:Social-twitter-icon.png|frameless|upright=0.1]] [https://twitter.com/TravisOsterman TravisOsterman]<br>[https://www.linkedin.com/in/travis-osterman-1850b236/ LinkedIn] |
|- | |- | ||
|} | |} | ||
Revision as of 17:11, 12 October 2020
| Page editor | Section editor | ||
|---|---|---|---|
 |
Amit Kulkarni, MBBS University of Minnesota Minneapolis, MN  AmitKulkarniMD
|
 |
Travis Osterman, DO, MS Vanderbilt University Nashville, TN TravisOsterman |
Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
3 regimens on this page
3 variants on this page
|
Metastatic disease
Capmatinib monotherapy
| back to top |
Regimen
| FDA-recommended dose |
| Study | Years of enrollment | Evidence |
|---|---|---|
| Wolf et al. 2020 (GEOMETRY mono-1) | NR | Phase II (RT) |
Biomarker Eligibility Criteria
- Biomarker: MET exon 14 skipping
Targeted therapy
- Capmatinib (Tabrecta) 400 mg PO twice per day with or without food
Continued indefinitely
References
- GEOMETRY mono-1: Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. link to original article contains protocol PubMed NCT02414139